Advances in development of a contraceptive vaccine against human chorionic gonadotropin

Autores
Talwar, Gursaran P.; Gupta, Jagdish C.; Rulli, Susana Beatriz; Sharma, Radhey S.; Nand, Kripa N.; Bandivdekar, Atmaram H.; Atrey, Nishu; Singh, Priyanka
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: There is continuing need for contraceptives. According to World Health Organization, 210 million pregnancies occur each year, out of which some 80 million are unintended. A vaccine offering privacy and periodic intake would be an attractive proposition.Areas covered: The article is a brief review of three vaccines developed against human chorionic gonadotropin (hCG) with progressively better attributes. Clinical trials have proven in more than one country the complete safety and reversibility of the anti-hCG vaccine(s) in women. Vaccination does not entail any disturbance in levels of reproductive tract hormones of the woman or any disturbance in menstrual regularity and bleeding profiles. Phase II clinical trials show the effective prevention of pregnancy in sexually active women of proven fertility. A recombinant vaccine amenable to industrial production has been developed; it induces substantially higher antibody titers in mice of four different genetic strains than those required to prevent pregnancy in women. Rigorous toxicology studies have been completed on this vaccine in rodents and marmosets.Expert opinion: This unique vaccine, requiring periodic intake and demonstrating no impairment of ovulation, hormonal profiles and menstrual regularity, is on the verge of final clinical trials under the aegis of the Indian Council of Medical Research and should be a valuable addition to the available contraceptives.
Fil: Talwar, Gursaran P.. Talwar Research Foundation; India
Fil: Gupta, Jagdish C.. Talwar Research Foundation; India
Fil: Rulli, Susana Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Sharma, Radhey S.. Indian Council Of Medical Research; India
Fil: Nand, Kripa N.. Jamia Hamdard University; India. Talwar Research Foundation; India
Fil: Bandivdekar, Atmaram H.. National Institute For Research In Reproductive Health; India
Fil: Atrey, Nishu. Talwar Research Foundation; India
Fil: Singh, Priyanka. Talwar Research Foundation; India
Materia
Contraception
Fertility Control
Human Chorionic Gonadotropin
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/76410
Acceder
id CONICETDig_06071f56a48b96b0f0e835bf80992702
oai_identifier_str oai:ri.conicet.gov.ar:11336/76410
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Advances in development of a contraceptive vaccine against human chorionic gonadotropinTalwar, Gursaran P.Gupta, Jagdish C.Rulli, Susana BeatrizSharma, Radhey S.Nand, Kripa N.Bandivdekar, Atmaram H.Atrey, NishuSingh, PriyankaContraceptionFertility ControlHuman Chorionic Gonadotropinhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Introduction: There is continuing need for contraceptives. According to World Health Organization, 210 million pregnancies occur each year, out of which some 80 million are unintended. A vaccine offering privacy and periodic intake would be an attractive proposition.Areas covered: The article is a brief review of three vaccines developed against human chorionic gonadotropin (hCG) with progressively better attributes. Clinical trials have proven in more than one country the complete safety and reversibility of the anti-hCG vaccine(s) in women. Vaccination does not entail any disturbance in levels of reproductive tract hormones of the woman or any disturbance in menstrual regularity and bleeding profiles. Phase II clinical trials show the effective prevention of pregnancy in sexually active women of proven fertility. A recombinant vaccine amenable to industrial production has been developed; it induces substantially higher antibody titers in mice of four different genetic strains than those required to prevent pregnancy in women. Rigorous toxicology studies have been completed on this vaccine in rodents and marmosets.Expert opinion: This unique vaccine, requiring periodic intake and demonstrating no impairment of ovulation, hormonal profiles and menstrual regularity, is on the verge of final clinical trials under the aegis of the Indian Council of Medical Research and should be a valuable addition to the available contraceptives.Fil: Talwar, Gursaran P.. Talwar Research Foundation; IndiaFil: Gupta, Jagdish C.. Talwar Research Foundation; IndiaFil: Rulli, Susana Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Sharma, Radhey S.. Indian Council Of Medical Research; IndiaFil: Nand, Kripa N.. Jamia Hamdard University; India. Talwar Research Foundation; IndiaFil: Bandivdekar, Atmaram H.. National Institute For Research In Reproductive Health; IndiaFil: Atrey, Nishu. Talwar Research Foundation; IndiaFil: Singh, Priyanka. Talwar Research Foundation; IndiaInforma Healthcare2015-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/76410Talwar, Gursaran P.; Gupta, Jagdish C.; Rulli, Susana Beatriz; Sharma, Radhey S.; Nand, Kripa N.; et al.; Advances in development of a contraceptive vaccine against human chorionic gonadotropin; Informa Healthcare; Expert Opinion on Biological Therapy; 15; 8; 8-2015; 1183-11901471-2598CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1517/14712598.2015.1049943info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14712598.2015.1049943info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:58:15Zoai:ri.conicet.gov.ar:11336/76410instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:58:15.335CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Advances in development of a contraceptive vaccine against human chorionic gonadotropin
title Advances in development of a contraceptive vaccine against human chorionic gonadotropin
spellingShingle Advances in development of a contraceptive vaccine against human chorionic gonadotropin
Talwar, Gursaran P.
Contraception
Fertility Control
Human Chorionic Gonadotropin
title_short Advances in development of a contraceptive vaccine against human chorionic gonadotropin
title_full Advances in development of a contraceptive vaccine against human chorionic gonadotropin
title_fullStr Advances in development of a contraceptive vaccine against human chorionic gonadotropin
title_full_unstemmed Advances in development of a contraceptive vaccine against human chorionic gonadotropin
title_sort Advances in development of a contraceptive vaccine against human chorionic gonadotropin
dc.creator.none.fl_str_mv Talwar, Gursaran P.
Gupta, Jagdish C.
Rulli, Susana Beatriz
Sharma, Radhey S.
Nand, Kripa N.
Bandivdekar, Atmaram H.
Atrey, Nishu
Singh, Priyanka
author Talwar, Gursaran P.
author_facet Talwar, Gursaran P.
Gupta, Jagdish C.
Rulli, Susana Beatriz
Sharma, Radhey S.
Nand, Kripa N.
Bandivdekar, Atmaram H.
Atrey, Nishu
Singh, Priyanka
author_role author
author2 Gupta, Jagdish C.
Rulli, Susana Beatriz
Sharma, Radhey S.
Nand, Kripa N.
Bandivdekar, Atmaram H.
Atrey, Nishu
Singh, Priyanka
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Contraception
Fertility Control
Human Chorionic Gonadotropin
topic Contraception
Fertility Control
Human Chorionic Gonadotropin
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: There is continuing need for contraceptives. According to World Health Organization, 210 million pregnancies occur each year, out of which some 80 million are unintended. A vaccine offering privacy and periodic intake would be an attractive proposition.Areas covered: The article is a brief review of three vaccines developed against human chorionic gonadotropin (hCG) with progressively better attributes. Clinical trials have proven in more than one country the complete safety and reversibility of the anti-hCG vaccine(s) in women. Vaccination does not entail any disturbance in levels of reproductive tract hormones of the woman or any disturbance in menstrual regularity and bleeding profiles. Phase II clinical trials show the effective prevention of pregnancy in sexually active women of proven fertility. A recombinant vaccine amenable to industrial production has been developed; it induces substantially higher antibody titers in mice of four different genetic strains than those required to prevent pregnancy in women. Rigorous toxicology studies have been completed on this vaccine in rodents and marmosets.Expert opinion: This unique vaccine, requiring periodic intake and demonstrating no impairment of ovulation, hormonal profiles and menstrual regularity, is on the verge of final clinical trials under the aegis of the Indian Council of Medical Research and should be a valuable addition to the available contraceptives.
Fil: Talwar, Gursaran P.. Talwar Research Foundation; India
Fil: Gupta, Jagdish C.. Talwar Research Foundation; India
Fil: Rulli, Susana Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Sharma, Radhey S.. Indian Council Of Medical Research; India
Fil: Nand, Kripa N.. Jamia Hamdard University; India. Talwar Research Foundation; India
Fil: Bandivdekar, Atmaram H.. National Institute For Research In Reproductive Health; India
Fil: Atrey, Nishu. Talwar Research Foundation; India
Fil: Singh, Priyanka. Talwar Research Foundation; India
description Introduction: There is continuing need for contraceptives. According to World Health Organization, 210 million pregnancies occur each year, out of which some 80 million are unintended. A vaccine offering privacy and periodic intake would be an attractive proposition.Areas covered: The article is a brief review of three vaccines developed against human chorionic gonadotropin (hCG) with progressively better attributes. Clinical trials have proven in more than one country the complete safety and reversibility of the anti-hCG vaccine(s) in women. Vaccination does not entail any disturbance in levels of reproductive tract hormones of the woman or any disturbance in menstrual regularity and bleeding profiles. Phase II clinical trials show the effective prevention of pregnancy in sexually active women of proven fertility. A recombinant vaccine amenable to industrial production has been developed; it induces substantially higher antibody titers in mice of four different genetic strains than those required to prevent pregnancy in women. Rigorous toxicology studies have been completed on this vaccine in rodents and marmosets.Expert opinion: This unique vaccine, requiring periodic intake and demonstrating no impairment of ovulation, hormonal profiles and menstrual regularity, is on the verge of final clinical trials under the aegis of the Indian Council of Medical Research and should be a valuable addition to the available contraceptives.
publishDate 2015
dc.date.none.fl_str_mv 2015-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/76410
Talwar, Gursaran P.; Gupta, Jagdish C.; Rulli, Susana Beatriz; Sharma, Radhey S.; Nand, Kripa N.; et al.; Advances in development of a contraceptive vaccine against human chorionic gonadotropin; Informa Healthcare; Expert Opinion on Biological Therapy; 15; 8; 8-2015; 1183-1190
1471-2598
CONICET Digital
CONICET
url http://hdl.handle.net/11336/76410
identifier_str_mv Talwar, Gursaran P.; Gupta, Jagdish C.; Rulli, Susana Beatriz; Sharma, Radhey S.; Nand, Kripa N.; et al.; Advances in development of a contraceptive vaccine against human chorionic gonadotropin; Informa Healthcare; Expert Opinion on Biological Therapy; 15; 8; 8-2015; 1183-1190
1471-2598
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1517/14712598.2015.1049943
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14712598.2015.1049943
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269510812303360
score 13.13397

Publicaciones similares